首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1738805

全球生物樣本庫市場：按產品類型、按生物樣本類型、按生物樣本庫類型、按服務、按應用、按地區和預測

Global Biobanks Market By Product, By Bio specimen Type, By Biobank Type, By Service, By Application, By Geographic Scope and Forecast

出版日期: 2025年05月06日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

生物庫市場規模及預測

2024 年生物銀行市場規模價值 711.4 億美元，預計到 2032 年將達到 1,091.8 億美元，2026 年至 2032 年的複合年成長率為 5.50%。

生物庫儲存生物樣本、遺傳資訊、健康記錄和其他相關數據，以供潛在的研究應用。

生物樣本庫在生物醫學研究中發揮著至關重要的作用，它使研究人員能夠獲得來自不同人群的大量、特徵明確的樣本。它們可用於研究疾病的遺傳易感性、開發個人化醫療治療方法，以及研究環境對人類健康的影響。

未來的生物樣本庫有望透過擁抱人工智慧和區塊鏈等現代技術來拓寬視野，從而更好地管理和分析數據。這項變革將促進跨研究領域的夥伴關係，加速生物標記的發現，協助個人化藥物開發，並最終改變精準醫療和醫療保健創新的未來。

全球生物樣本庫市場動態

影響全球生物銀行市場的關鍵市場動態是：

關鍵市場促進因素

個人化醫療需求日益成長：個人化醫療需求日益成長：過去十年，個人化醫療的需求持續成長。雖然目前尚無確切數據，但眾多醫學協會和研究機構已註意到市場對此領域的興趣日益濃厚。精準醫療市場預計將大幅擴張，一些預測顯示，2020年至2025年的複合年成長率將達到10-12%。

生物標記研究日益受到關注：近年來，生物標記研究取得了顯著進展。全球生物標記市場正在蓬勃發展，一些預測顯示，2019年至2024年的複合年成長率將達到13-15%。製藥和生物技術行業研發支出的增加、癌症發生率的上升以及診斷技術的進步推動了這一成長。

生物醫學研究和藥物開發的成長：生物樣本庫幫助製藥和生物技術公司加速藥物發現和開發流程。研究人員可以利用豐富的生物資訊來識別新的藥物標靶、檢驗治療方法方案並最佳化臨床試驗設計，從而縮短新藥上市時間和降低成本。

技術進步：樣本採集、儲存和管理領域的技術進步顯著提高了生物樣本庫的效率和可擴展性。自動化、機器人技術和雲端基礎技術使生物樣本庫能夠更有效率地儲存和檢索樣本，長期保持樣本完整性，並支援全球實驗室之間的無縫資料共用。

主要問題

倫理與法律考量：生物樣本庫必須應對權限、隱私和資料保護等嚴峻的倫理與法律體制。確保遵守跨司法管轄區的法規，同時維護透明度和捐贈者權利，是一項重大挑戰。

永續性和資金：生物樣本庫需要大量的資金來維護基礎設施、儲存樣本和管理資料。公共和私人生物樣本庫在確保長期資金和長期永續性的同時，也面臨預算約束的持續挑戰。

樣本品質與標準化：維護樣本完整性、確保統一的採集技術、減少分析前的差異性，都是生物樣本庫建置中的重要議題。樣本處理、儲存條件和元資料記錄的差異會影響研究的可重複性和研究結果的可靠性。

資料整合與相容性：整合來自生物庫的各種生物、臨床和基因組資料在資料標準、與其他系統的相容性、資料安全等方面帶來了技術挑戰。資料格式的協調和有效資料共用框架的建立對於最大限度地利用生物庫資源進行研究合作和臨床應用至關重要。

主要趨勢

擴大特定疾病生物庫：針對特定疾病或病症（如癌症、心血管疾病、罕見基因異常等）創建專門生物庫的趨勢日益成長。這些專門的生物庫從患有特定疾病的個人收集樣本和數據，從而實現更有針對性的研究和個人化治療的開發。

巨量資料與人工智慧的融合：生物樣本庫擴大使用巨量資料分析和人工智慧 (AI) 從海量資料集中提取有價值的洞察。人工智慧演算法利用來自多個資訊來源的廣泛生物和臨床數據，幫助識別生物標記、預測病情進展並最佳化治療策略。

全球合作與數據共用：生物樣本庫、研究機構和製藥公司正在全球合作。促進資料共用、流程標準化和倫理標準協調的努力，使得人們能夠獲得多樣化的樣本集，並加速跨境科學發現。

虛擬生物樣本庫數位雙胞胎的興起：虛擬生物樣本庫正日益普及，其數位模型可模擬真實生物樣本和資料的屬性。這些數位雙胞胎使研究人員無需真實樣本即可進行虛擬測試、增強研究設計並預測結果，從而降低成本並提高研究效率。

They play an important role in biomedical research by giving researchers access to vast, well-characterized sample collections from a variety of populations. Biobanks can be used to examine genetic predispositions to diseases, develop personalized medicine treatments, and investigate environmental influences on human health.

In the future, biobanks are expected to broaden their scope by incorporating modern technologies such as artificial intelligence and blockchain for better data administration and analysis. This change will enable greater partnerships across research disciplines, speed biomarker discovery, and aid in the development of tailored medicines, ultimately changing the future of precision medicine and healthcare innovation.

Global Biobanks Market Dynamics

The key market dynamics that are shaping the global biobanks market include:

Key Market Drivers:

Rising Demand for Personalized Medicine: The demand for individualized medication has been gradually increasing during the last decade. While I do not have exact figures, numerous health groups and research institutions have indicated increased interest in this sector. The precision medicine market is expected to expand significantly, with some projections indicating a compound annual growth rate (CAGR) of 10-12% between 2020 and 2025.

Increasing Focus on Biomarker Research: Biomarker research is witnessing significant progress in recent years. The global biomarkers market is rising, with some forecasts predicting a CAGR of 13-15% from 2019 to 2024. This expansion is being driven by causes such as increase in R&D spending in the pharmaceutical and biotechnology industries, rising cancer rates, and advances in diagnostic technologies.

Growth in Biomedical Research and Drug Development: Biobanks help pharmaceutical and biotechnology businesses accelerate medication discovery and development procedures. Researchers can use extensive biological information to identify new drug targets, validate therapeutic ideas, and optimize clinical trial designs, lowering the time and costs associated with bringing new medicines to market.

Technological Advancement: Technological advancements in sample collection, storage, and management have dramatically improved biobank efficiency and scalability. Automation, robots, and cloud-based technologies allow biobanks to store and retrieve samples more efficiently, maintain sample integrity over time, and support seamless data sharing across research institutions around the world.

Key Challenges:

Ethical and Legal Considerations: Biobanks must navigate difficult ethical and legal frameworks related to permission, privacy, and data protection. Ensuring compliance with rules across several jurisdictions while retaining transparency and donor rights presents substantial problems.

Sustainability and Funding: Biobanks require significant financial resources to maintain infrastructure, store samples, and manage data. Both public and private biobanks have continual issues in securing long-term funding while adhering to budget limits and guaranteeing long-term sustainability.

Sample Quality and Standardization: Maintaining sample integrity, assuring uniform collection techniques, and reducing pre-analytical variability are all key problems in biobanking. Variations in sample handling, storage conditions, and metadata recording can have an impact on research reproducibility and the reliability of study results.

Data Integration and Compatibility: Integrating varied biological, clinical, and genomic data from biobanks presents technical issues such as data standards, compatibility with other systems, and data security. Harmonizing data formats and building effective data sharing frameworks are critical for making the most of biobank resources in research collaborations and clinical applications.

Key Trends:

Expansion of Disease-certain Biobanks: There is an increasing trend of creating biobanks dedicated to certain diseases or conditions, such as cancer, cardiovascular disease, and uncommon genetic abnormalities. These specialized biobanks collect samples and data from individuals with specific illnesses, allowing for more focused research and individualized treatment development.

Integration of Big Data and AI: Biobanks are increasingly using big data analytics and artificial intelligence (AI) to extract valuable insights from massive datasets. AI algorithms aid in the identification of biomarkers, disease progression prediction, and treatment strategy optimization using extensive biological and clinical data from numerous sources.

Global Collaboration and Data Sharing Initiatives: Biobanks, research institutes, and pharmaceutical corporations are working together on a global scale. Initiatives that promote data sharing, procedure standardization, and ethical norms harmonization enable greater access to different sample sets and accelerate scientific discoveries across borders.

The Rise of Virtual Biobanks and Digital Twins: Virtual biobanks, in which digital models mimic the properties of genuine biological samples and data, are gaining popularity. These digital twins allow researchers to run virtual tests, enhance study designs, and forecast outcomes without requiring actual samples, lowering costs and increasing research efficiency.

Global Biobanks Market Regional Analysis

Here is a more detailed regional analysis of the global biobanks market:

North America:

North America is anticipated to hold major share in the global biobanks market over the forecast period.

North America has a solid foundation in research and development, with major government and commercial funding supporting biobank activities.

The region has a well-established healthcare infrastructure and a high prevalence of chronic diseases, which increases demand for biospecimens in research to improve diagnosis and treatment.

Furthermore, an increasing emphasis on personalized and precision medicine increases the demand for biobanks in North America. This convergence of circumstances establishes North America as the clear worldwide biobanks industry leader.

Asia Pacific:

In terms of global biobanks market growth, the Asia Pacific region is unquestionably the leader. This rapid increase can be due to a variety of things.

Governments in China, Japan, and South Korea are increasing their investments in R&D. Second, the rising frequency of chronic diseases, combined with a developing healthcare infrastructure, increases the demand for biospecimens utilized in research to improve diagnoses and treatments.

Increasing awareness of the use of biobanks in personalized treatment is moving the market forward. This convergence of circumstances is enabling the Asia Pacific region exhibit fastest growth in the biobank market.

Global Biobanks Market: Segmentation Analysis

The Global Biobanks Market is segmented on the basis of By Product, By Bio Specimen Type, By Biobank Type, By Service and By Application, By Geography.

Biobanks Market, By Product

Laboratory Information Management System (LIMS)
Biobanking Equipment

Based on Product, the Global Biobanks Market is segmented into LIMS and Biobanking Equipment. Biobanking Equipment is the largest segment of the global biobanks market, since it includes key tools for sample collection, storage, and preservation. LIMS (Laboratory Information Management Systems) is the fastest-growing market, driven by the increased demand for effective data management, sample tracking, and the incorporation of modern digital technologies into biobanking processes.

Biobanks Market, By Bio Specimen Type

Organs
Stem Cells

Based on Bio specimen Type, the Global Biobanks Market is segmented into Organs and Stem Cells. Organs are the most common bio specimen type in the worldwide biobanks market, owing to their vital role in transplant research and other scientific investigations. Stem cells are the fastest-growing segment, owing to their enormous potential in regenerative medicine, disease modeling, and tailored treatment strategies.

Biobanks Market, By Biobank Type

Real
Virtual

Based on Biobank Type, the Global Biobanks Market is segmented into Real and Virtual. Real biobanks are the most common form in the global biobanks market, as they were originally established for the physical collection, storage, and management of biological samples. Virtual biobanks are the fastest-growing segment, spurred by advances in digital technologies and rising demand for remote access to biological data for research reasons.

Biobanks Market, By Service

Biobanking & Repository
Lab Processing
Qualification/Validation
Cold Chain Logistics

Based on Service, the Global Biobanks Market is segmented into Biobanking & Repository, Lab Processing, Qualification/Validation, and Cold Chain Logistics. Biobanking & Repository is the dominating service sector in the global biobanks market, as it is biobanks' primary duty to collect, store, and manage biological samples. Cold Chain Logistics is the fastest-growing market, driven by the growing need to preserve biological samples' integrity throughout transportation and storage under strict temperature control settings.

Biobanks Market, By Application

Therapeutics
Drug Discovery & Clinical Research
Clinical Diagnostics

Based on Application, the Global Biobanks Market is segmented into Therapeutics, Drug Discovery & Clinical Research, and Clinical Diagnostics. Drug Discovery & Clinical Research dominates the worldwide biobanks market, owing to the widespread usage of biobanked samples in the development of novel medications and clinical trials. Clinical Diagnostics is the fastest-growing market, driven by rising demand for precision medicine and the use of biobanks to uncover illness biomarkers and create diagnostic tests.

Biobanks Market, By Geography

North America
Europe
Asia Pacific
Rest of the World

Based on the Geography, the Global Biobanks Market are classified into North America, Europe, Asia Pacific, and Rest of the World. North America dominates the global biobanks market, owing to advanced healthcare infrastructure, significant research funding, and a large number of established biobanks. Asia Pacific is the fastest-growing area, driven by increased healthcare spending, increased awareness of customized treatment, and the expansion of biobank projects.

Key Players

The "Global Biobanks Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Thermo Fisher Scientific, Merck KGaA, QIAGEN, Hamilton Company, Avantor, BD (Becton, Dickinson and Company), Promega Corporation, Brooks Automation, Biovault Family.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Biobanks Market: Recent Developments
In September 2023, Sheikh Khaled bin Mohamed, Abu Dhabi's Crown Prince, has approved plans to use human stem cells and tissues to conduct personalized medical research. He approved the plan during a meeting of the Abu Dhabi Executive Council. Members of Abu Dhabi's Department of Health presented the plans to Sheikh Khaled. According to the Abu Dhabi Media Office, the initiative would establish a biobank to enable the provision of personalised medicine through innovative treatment programmes that use human stem cells and tissues to conduct medical research.
In Jun 2022, Mars Petcare today unveiled an unparalleled scientific endeavor aimed at improving understanding of pet health and disease, as well as assisting scientists and veterinarians in developing personalized pet care. The MARS PETCARE BIOBANKTM intends to be the largest and most comprehensive real-world study of its type, collecting 20,000 pets (10,000 dogs and 10,000 cats) from across the United States over a ten-year period.